Heightened autoantibody immune response to citrullinated calreticulin in bronchiectasis: Implications for rheumatoid arthritis
Research article published in The international journal of biochemistry & cell biology (2017)
Abstract
Calreticulin (CRT) and citrullinated (citCRT) are implicated in rheumatoid arthritis (RA) pathology. citCRT binds to RA shared epitopes (SE) on HLA-DR molecules with high affinity and triggers pro-inflammatory events in adjacent cells. The aim of the study was to detect the presence of citCRT prior to developing RA and evaluate if citCT is a target for autoantibodies in RA cohorts with and without lung disease. Antibodies were assessed by ELISA against native CRT, citCRT and general protein citrullination, in sera from 50 RA patients without lung disease, 122 bronchiectasis (BR) patients, 52 bronchiectasis patients with RA (BRRA), 87 asthma patients and 77 healthy controls (HC). Serum citCRT was detected by immunoblotting and mass spectrometry. Genomic DNA was genotyped for HLA-DRB1 alleles. Patients were assessed for DAS28, rheumatoid factor, and anti-cyclic citrullinated peptide antibodies. Extracellular citCRT was detected in BR patients sera prior to them developing RA. A citCRT SE binding peptide GEWKPR261citQIDNPDYK was identified. Anti-CRT antibodies were observed in 18% of BR patients with or without RA. Anti-citCRT antibodies were observed in ∼35% of BR or RA patients, increasing to 58% in BRRA patients. In the RA alone patients 7/20 (35%) who were negative for RF and anti-CCP were anti-CRT antibody positive and had higher DAS28 scores than triple negative RA alone patients. Three of the four BR patients who developed RA over 18 months were anti-citCRT+ve SE+ve. The detection of citCRT in BR and development of anti-citCRT in BR patients suggests citCRT antigens are early targets of antigenicity in these patients, especially in SE+ve patients prior to the onset of RA.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Calreticulin (CRT) and citrullinated (citCRT) are implicated in rheumatoid arthritis (RA) pathology.
Por qué esto importa para la hirudoterapia
Este estudio investigó las respuestas de autoanticuerpos contra la calreticulina citrulinada (citCRT) en bronquiectasias y artritis reumatoide, analizando sueros de 50 pacientes con AR sin enfermedad pulmonar, 122 pacientes con bronquiectasias, 52 pacientes con bronquiectasias y AR, 87 pacientes con asma y 77 controles sanos mediante ELISA, inmunotransferencia y espectrometría de masas. Se detectó citCRT extracelular en pacientes con bronquiectasias antes del desarrollo de AR, y se encontraron anticuerpos anti-citCRT en aproximadamente el 35% de los pacientes con BR o AR, aumentando al 58% en los pacientes con BRRA. Este artículo no tiene relación con la hirudoterapia, la terapia con sanguijuelas ni con el secretoma de las sanguijuelas. El resumen no menciona sanguijuelas, hirudina ni ningún compuesto derivado de sanguijuelas, y la relevancia con el ámbito de la ASH es inexistente.
Citación
Heightened autoantibody immune response to citrullinated calreticulin in bronchiectasis: Implications for rheumatoid arthritis
Clarke A et al. · The international journal of biochemistry & cell biology, 2017
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026